Verastem Inc (NASDAQ: VSTM) has seen a rise in its stock price by 5.21 in relation to its previous close of 7.15. However, the company has experienced a 25.37% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-01-29 that BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.v.
Is It Worth Investing in Verastem Inc (NASDAQ: VSTM) Right Now?
Additionally, the 36-month beta value for VSTM is 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VSTM is 39.48M and currently, short sellers hold a 15.11% ratio of that float. The average trading volume of VSTM on March 12, 2025 was 1.37M shares.
VSTM’s Market Performance
The stock of Verastem Inc (VSTM) has seen a 25.37% increase in the past week, with a 31.97% rise in the past month, and a 33.14% gain in the past quarter. The volatility ratio for the week is 10.18%, and the volatility levels for the past 30 days are at 6.62% for VSTM. The simple moving average for the last 20 days is 23.89% for VSTM stock, with a simple moving average of 87.77% for the last 200 days.
Analysts’ Opinion of VSTM
Many brokerage firms have already submitted their reports for VSTM stocks, with BTIG Research repeating the rating for VSTM by listing it as a “Buy.” The predicted price for VSTM in the upcoming period, according to BTIG Research is $20 based on the research report published on December 31, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see VSTM reach a price target of $13. The rating they have provided for VSTM stocks is “Buy” according to the report published on September 30th, 2024.
BTIG Research gave a rating of “Buy” to VSTM, setting the target price at $27 in the report published on November 21st of the previous year.
VSTM Trading at 28.91% from the 50-Day Moving Average
After a stumble in the market that brought VSTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.36% of loss for the given period.
Volatility was left at 6.62%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares surge +30.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +90.36% upper at present.
During the last 5 trading sessions, VSTM rose by +25.00%, which changed the moving average for the period of 200-days by -36.87% in comparison to the 20-day moving average, which settled at $6.07. In addition, Verastem Inc saw 45.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VSTM starting from Paterson Dan, who sale 858 shares at the price of $5.70 back on Feb 04 ’25. After this action, Paterson Dan now owns 346,723 shares of Verastem Inc, valued at $4,891 using the latest closing price.
Paterson Dan, the President and CEO of Verastem Inc, sale 8,568 shares at $5.24 during a trade that took place back on Jan 13 ’25, which means that Paterson Dan is holding 347,581 shares at $44,896 based on the most recent closing price.
Stock Fundamentals for VSTM
Current profitability levels for the company are sitting at:
- -11.32 for the present operating margin
- 1.0 for the gross margin
The net margin for Verastem Inc stands at -9.24. The total capital return value is set at -1.29. Equity return is now at value -136.87, with -61.78 for asset returns.
Based on Verastem Inc (VSTM), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -2.64. The debt to equity ratio resting at 3.75. The interest coverage ratio of the stock is -25.24.
Currently, EBITDA for the company is -83.17 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 26.13. The receivables turnover for the company is 50.57for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.23.
Conclusion
In conclusion, Verastem Inc (VSTM) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
